Adagio Therapeutics website screenshot

Adagio Therapeutics

Adagio Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 to discover, develop, and commercialize antibody-based therapies for serious infectious diseases, with an initial focus on SARS-CoV-2 and other respiratory viruses. Its lead programs centered on monoclonal antibody candidates engineered for high potency and broad, evolution-resistant neutralization. The company was renamed Invivyd, Inc. in 2023 (Nasdaq: IVVD) and now advances antibody medicines such as PEMGARDA and the VYD2311 candidate. It was surfaced as a portfolio company of GV (Google Ventures) and added to the API Evangelist network. As a life-sciences therapeutics company it publishes no public developer API, SDK, or documentation surface; this profile captures corporate identity and policy links only.

Adagio Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Pharmaceuticals, and Antibody Therapeutics.

🌐 Visit website 📡 Source on GitHub
9.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyLife SciencesBiotechnologyPharmaceuticalsAntibody TherapeuticsInfectious Diseases

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 9.0/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/adagio-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Adagio Therapeutics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService
TermsOfService
 PrivacyPolicy
PrivacyPolicy

Company 2

The organization behind the API

Website
Website
 InvestorRelations
InvestorRelations

Source (apis.yml)

apis.yml Raw ↑ 
aid: adagio-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/adagio-therapeutics.png
name: Adagio Therapeutics
description: 'Adagio Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 to discover, develop, and
  commercialize antibody-based therapies for serious infectious diseases, with an initial focus on SARS-CoV-2 and other respiratory
  viruses. Its lead programs centered on monoclonal antibody candidates engineered for high potency and broad, evolution-resistant
  neutralization. The company was renamed Invivyd, Inc. in 2023 (Nasdaq: IVVD) and now advances antibody medicines such as
  PEMGARDA and the VYD2311 candidate. It was surfaced as a portfolio company of GV (Google Ventures) and added to the API
  Evangelist network. As a life-sciences therapeutics company it publishes no public developer API, SDK, or documentation
  surface; this profile captures corporate identity and policy links only.'
url: https://raw.githubusercontent.com/api-evangelist/adagio-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
x-former-name: Adagio Therapeutics
x-current-name: Invivyd, Inc.
x-no-api-surface: true
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Life Sciences
- Biotechnology
- Pharmaceuticals
- Antibody Therapeutics
- Infectious Diseases
apis: []
common:
- type: DomainSecurity
  url: security/adagio-therapeutics-domain-security.yml
- type: Website
  url: https://www.invivyd.com
- type: InvestorRelations
  url: https://investors.invivyd.com/
- type: TermsOfService
  url: https://www.invivyd.com/terms/
- type: PrivacyPolicy
  url: https://www.invivyd.com/privacy/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence